Huangtengsu glucose injection, a class 2 new drug of Anhui Shuanghe Pharmaceutical Co., Ltd., took 9 years to obtain the production approval

Anhui Shuanghe Pharmaceutical Co., Ltd., a wholly-owned subsidiary of China Resources Shuanghe Pharmaceutical Co., Ltd., has applied for the production of Huangtengsu glucose injection (acceptance No.: x0407935), a class 2 new drug, which has been prepared and certified by the State Food and Drug Administration and is in the status of awaiting approval This means that for 9 years, the Huangtengsu glucose injection finally ushered in substantive progress It is understood that Huangtengsu glucose injection is a pure natural plant drug developed by our country This injection is the exclusive variety of Anhui Shuanghe The company applied for the drug as early as 2004, and applied for patent in 2005 Then it was rated as a major science and technology special project in Wuhu City in 2008 Patent information shows that the injection is not only effective and stable, but also has no adverse reactions In addition, Huangtengsu glucose injection is widely used in the treatment of gynecological diseases, with the efficacy of anti bacteria and anti viral infection According to IMS data, the global female drug market in 2012 has reached $about 130000000000, showing a sustained growth trend, and is expected to exceed $160 billion in 2014 According to the financial report of China Resources Shuanghe, Anhui Shuanghe obtained the certificate of Anhui high tech enterprise in 2011, and can enjoy 15% income tax preference from 2011 to 2013 The approval of Huangtengsu glucose injection will undoubtedly bring large-scale performance release to Anhui Shuanghe and China Resources Shuanghe